Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
624 studies found for:    "gene therapy" OR "gene transfer" OR "virus delivery"
Show Display Options
Rank Status Study
1 Recruiting Gene Transfer for Patients With Sickle Cell Disease
Conditions: Sickle Cell Disease;   Sickle Cell Anemia
Intervention: Genetic: Gene transfer
2 Active, not recruiting EndocardialVascularEndothelialGrowth Factor D(VEGF-D)Gene Therapy for the Treatment of Severe Coronary Heart Disease
Conditions: Angina Pectoris;   Myocardial Infarction
Intervention: Biological: VEGF-D gene transfer
3 Completed Gene Transfer Therapy for Treating Children and Adults With Limb Girdle Muscular Dystrophy Type 2D (LGMD2D)
Condition: Muscular Dystrophies
Interventions: Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- First cohort;   Genetic: Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort
4 Recruiting Long-Term Follow-Up of Recipient of Gene Transfer Research
Conditions: Retroviridae Infections;   Cancer
Interventions: Other: Blood Tests;   Behavioral: Questionnaires
5 Recruiting Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector
Condition: Severe Combined Immunodeficiency
Intervention: Biological: Gene transfer
6 Active, not recruiting Gene Therapy for X-linked Severe Combined Immunodeficiency
Condition: X-linked Severe Combined Immunodeficiency
Intervention: Other: Gene transfer
7 Recruiting Gene Therapy for X-CGD
Condition: X-linked Chronic Granulomatous Disease
Intervention: Genetic: ex-vivo gene-therapy
8 Not yet recruiting p53 Gene Therapy in Treatment of Diabetes Concurrent With Hepatocellular Carcinoma
Conditions: HCC;   Diabetes
Interventions: Drug: p53 gene therapy;   Drug: Trans-catheter embolization
9 Recruiting Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome
Condition: Wiskott-Aldrich Syndrome
Intervention: Biological: Retrovirus-mediated gene transfer
10 Recruiting A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)
Condition: Homozygous Familial Hypercholesterolemia
Intervention: Genetic: AAV directed hLDLR gene therapy
11 Not yet recruiting Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer
Condition: Pancreatic Adenocarcinoma
Interventions: Drug: Gene Therapy product CYL-02;   Drug: Gemcitabine
12 Completed Gene Therapy for ADA-SCID
Condition: Severe Combined Immunodeficiency Syndrome
Intervention: Genetic: gene transduced PBL and/or gene transduced HSC
13 Recruiting Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis
Condition: Gene Transfer
Intervention: Biological: RS1 AAV Vector
14 Completed Gene Therapy of Pancreatic Ductal Adenocarcinoma
Condition: Pancreatic Adenocarcinoma
Intervention: Genetic: Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes
15 Completed Follow-up of Breast Cancer and Multiple Myeloma Patients Previously Enrolled in NIH Gene Therapy Studies
Condition: Gene Transfer
Intervention:
16 Suspended Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
Conditions: X-linked Severe Combined Immunodeficiency;   XSCID;   SCID-X1;   Gamma C-Deficient SCID
Interventions: Other: Gene-modified CD34+ Hematopoietic stem cells;   Drug: Busulfan
17 Active, not recruiting ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID
Condition: Immunologic Deficiency Syndromes
Intervention: Genetic: Gene transduced CD34+ cells
18 Recruiting Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products
Conditions: Severe Combined Immunodeficiency;   Malignancy, Hematologic;   Neuroblastoma;   Neoplasm;   Mucopolysaccharidosis I
Intervention: Procedure: Venipuncture
19 Withdrawn Quality of Life and Neuropsychiatric Sequelae in Patients Treated With Gene Therapy for ADA-SCID and in Their Parents
Condition: ADA-SCID
Intervention:
20 Active, not recruiting Gene Therapy for Wiskott-Aldrich Syndrome
Condition: Wiskott-Aldrich Syndrome
Intervention: Genetic: Autologous CD34 positive cells transduced with WAS encoding lentiviral vector.

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.